InvestorsHub Logo
Followers 13
Posts 865
Boards Moderated 0
Alias Born 02/17/2017

Re: LongPennypincher post# 37202

Thursday, 02/21/2019 1:46:42 PM

Thursday, February 21, 2019 1:46:42 PM

Post# of 232880
Edit: I see a lawyer beat me to it. I should probably stay in my lane.

No need for CYDY to patent it for a new use. Patents, approvals, and marketing exclusivity are all separate concepts. It may come in handy, but really... someone would have to develop a more effective and/or safer CCR5 inhibitor than leronlimab for it to really matter from a patent standpoint, i.e. developing similar technology without infringing on FDA exclusivity protections. Good luck with that... The cancer patent means that it would likely be exceptionally difficult (patents are notoriously complicated) for Merck to commercialize maraviroc for cancer, which is incredibly helpful in terms of us being first to market. Interestingly, if you read Pestell's patent closely, I believe he needed CYDY more than the other way around from an IP perspective.

I don't believe that CYDY has bulletproof IP for CCR5 inhibition as an HIV therapy. I could be wrong about that, but I don't believe that they have something covering that so completely as Pestell's (now CytoDyn's) patent for CCR5 inhibition for treating cancer metastasis.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News